Developing a vaccine to protect against antibiotic-resistant Acinetobacter baumannii infections
Official title: A Subunit Vaccine Against Acinetobacter Baumannii
Funded at Biological Mimetics, INC. · NIH-11068597 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from tough infections caused by a bacteria called Multi-Drug Resistant Acinetobacter baumannii, which is a big concern in hospitals.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biological Mimetics, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | December 23, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $288,360 |
| NIH project number | 1R43AI189041-01 |
| Project ID | NIH-11068597 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for MDR-AB infections, such as patients in hospitals or those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for antibiotic-resistant infections or those who are not currently in healthcare settings may not benefit from this research.
What this research studies
This research focuses on creating a new vaccine to combat Multi-Drug Resistant Acinetobacter baumannii (MDR-AB), a significant threat to global health. The project aims to identify key components of the bacteria that can stimulate a strong immune response, develop a prototype vaccine formulation, and evaluate its effectiveness through laboratory tests. By using advanced immunological techniques and molecular biology tools, the researchers hope to provide a preventive measure against these dangerous infections, which are particularly prevalent in healthcare settings.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of MDR-AB infections and reliance on antibiotics.
How similar studies have gone: While the approach of developing a vaccine against MDR-AB is innovative, similar efforts in vaccine development against other antibiotic-resistant bacteria have shown promise, indicating potential for success.
Where this research is happening
-
Biological Mimetics, INC.
Frederick, United States Active
Researchers
- Principal investigator: Dollery, Stephen Jeffrey — Biological Mimetics, INC.
- Study coordinator: Dollery, Stephen Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
Vaccine candidate to prevent infections from Acinetobacter baumannii
A small SBIR project is developing a new vaccine to protect people from dangerous Acinetobacter baumannii infections.
-
A simple, machine-free malaria test
A quick, low-cost CRISPR-based malaria test that people in low-resource areas can run without lab equipment or advanced training.
-
Creating a vaccine to prevent Staph Aureus infections
This study is working on a new vaccine to help protect people from MRSA, a tough infection often caught in hospitals, and they're testing different versions in animals to find the best one that boosts the immune system to fight off this infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.